Total Payments
$1,492
2024 Payments
$682.43
Companies
25
Transactions
66
Medicare Patients
11,989
Medicare Billing
$3.5M
Payment Breakdown by Category
Food & Beverage$1,341 (89.9%)
Education$150.96 (10.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,341 | 62 | 89.9% |
| Education | $150.96 | 4 | 10.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $328.72 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $227.55 | 9 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | $0 (2024) |
| PFIZER INC. | $125.24 | 7 | $0 (2023) |
| Amgen Inc. | $82.87 | 5 | $0 (2023) |
| Celgene Corporation | $74.56 | 4 | $0 (2024) |
| BeiGene USA, Inc. | $67.66 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $47.41 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $43.53 | 3 | $0 (2024) |
| AbbVie Inc. | $32.33 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $682.43 | 25 | JAZZ PHARMACEUTICALS INC. ($150.00) |
| 2023 | $199.06 | 11 | PFIZER INC. ($34.32) |
| 2022 | $432.90 | 19 | Janssen Biotech, Inc. ($164.60) |
| 2021 | $127.72 | 7 | Novartis Pharmaceuticals Corporation ($47.21) |
| 2018 | $14.47 | 1 | PFIZER INC. ($14.47) |
| 2017 | $34.99 | 3 | PFIZER INC. ($12.45) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.45 | General |
| 12/10/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $22.60 | General |
| Category: Hematology/Oncology | ||||||
| 11/26/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $22.18 | General |
| Category: Oncology | ||||||
| 11/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $29.32 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $29.63 | General |
| Category: Oncology | ||||||
| 10/17/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Novartis Pharmaceuticals Corporation | LUTATHERA (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Oncology | ||||||
| 09/05/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $18.88 | General |
| 08/23/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.56 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $19.92 | General |
| Category: Hematology | ||||||
| 07/25/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $30.57 | General |
| Category: Oncology | ||||||
| 07/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $27.32 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $21.56 | General |
| Category: Hematology | ||||||
| 06/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TALVEY | Food and Beverage | In-kind items and services | $17.17 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Oncology | ||||||
| 05/31/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Oncology | ||||||
| 04/11/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $18.41 | General |
| Category: Hematology | ||||||
| 04/03/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $17.88 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA, TALVEY | Food and Beverage | In-kind items and services | $15.84 | General |
| Category: Oncology | ||||||
| 03/12/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $150.00 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/09/2024 | Pharmacosmos Therapeutics Inc. | COSELA (Drug) | Food and Beverage | In-kind items and services | $17.49 | General |
| Category: HEMATOLOGY | ||||||
| 01/25/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 67 | 3,780 | 67,749 | $4.5M | $1.0M |
| 2022 | 55 | 3,152 | 61,044 | $4.2M | $1.0M |
| 2021 | 46 | 2,534 | 34,151 | $2.7M | $870,309 |
| 2020 | 41 | 2,523 | 34,538 | $2.1M | $636,093 |
Total Patients
11,989
Total Services
197,482
Medicare Billing
$3.5M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 24 | 6,900 | $1.1M | $297,209 | 27.4% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 12 | 7,500 | $660,000 | $177,128 | 26.8% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 14 | 3,780 | $514,080 | $145,175 | 28.2% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 23 | 3,240 | $207,360 | $58,983 | 28.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 341 | 592 | $230,880 | $52,761 | 22.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 177 | 349 | $146,929 | $32,913 | 22.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 23 | 26 | $115,622 | $28,141 | 24.3% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 12 | 1,140 | $193,800 | $24,782 | 12.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 94 | 123 | $67,650 | $15,914 | 23.5% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 60 | 212 | $44,520 | $14,896 | 33.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 46 | 9,900 | $59,400 | $13,560 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 194 | 228 | $63,156 | $13,385 | 21.2% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 17 | 81 | $48,843 | $10,783 | 22.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 606 | 1,270 | $36,830 | $9,647 | 26.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 598 | 1,143 | $10,287 | $9,579 | 93.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 54 | 54 | $36,342 | $8,790 | 24.2% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 16 | 2,170 | $292,950 | $7,952 | 2.7% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 18 | 1,320 | $33,000 | $7,467 | 22.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $30,540 | $7,087 | 23.2% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 33 | 102 | $23,868 | $5,353 | 22.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 87 | $18,618 | $5,230 | 28.1% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 23 | 26 | $39,858 | $5,096 | 12.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 38 | $22,610 | $5,010 | 22.2% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 18 | 29 | $17,777 | $4,988 | 28.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 104 | 222 | $22,866 | $4,685 | 20.5% |
About Dr. Charles Bryan, M.D
Dr. Charles Bryan, M.D is a Hematology healthcare provider based in Asheville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1831189877.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Charles Bryan, M.D has received a total of $1,492 in payments from pharmaceutical and medical device companies, with $682.43 received in 2024. These payments were reported across 66 transactions from 25 companies. The most common payment nature is "Food and Beverage" ($1,341).
As a Medicare-enrolled provider, Bryan has provided services to 11,989 Medicare beneficiaries, totaling 197,482 services with total Medicare billing of $3.5M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Asheville, NC
- Active Since 10/21/2005
- Last Updated 01/10/2023
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1831189877
Products in Payments
- DARZALEX (Biological) $180.08
- ZEPZELCA (Drug) $150.00
- Pomalyst (Drug) $74.56
- BRUKINSA (Drug) $67.66
- Kyprolis (Drug) $64.65
- IMBRUVICA (Drug) $56.07
- TECVAYLI (Biological) $53.33
- PROMACTA (Drug) $48.69
- PIQRAY (Drug) $47.21
- XTANDI (Drug) $45.55
- INLYTA (Drug) $40.63
- ERLEADA (Drug) $39.24
- TABRECTA (Drug) $31.07
- KISQALI (Drug) $30.57
- KEYTRUDA (Biological) $29.32
- Xtandi (Drug) $28.35
- Nubeqa (Drug) $27.32
- PLUVICTO (Drug) $25.02
- SCEMBLIX (Drug) $23.56
- LIBTAYO (Biological) $23.03
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Asheville
Dr. Sean Warsch, M.d, M.D
Hematology — Payments: $39,996
Hematology $39,996
Dr. Martin Palmeri, M.d.,M.b.a, M.D.,M.B.A
Hematology — Payments: $12,737
Hematology $12,737
Wieslawa Pekal, M.d, M.D
Hematology — Payments: $8,977
Hematology $8,977
Dr. Trevor Austin, Md, MD
Hematology — Payments: $3,361
Hematology $3,361
Dr. Andrew Beardsley, M.d, M.D
Hematology — Payments: $1,529
Hematology $1,529
Rachel Raab, Md, MD
Hematology — Payments: $1,394
Hematology $1,394